One-Pot Synthesis of Alkyl Styryl Sulfides Free from Transition Metal/Ligand Catalyst and Thiols http://onlinelibrary.wiley.com/doi/10.1002/ejoc.201201163/abstract European Journal of Organic Chemistry Early View (Online Version of Record published before inclusion in an issue) Adrián A. Heredia and Alicia B. Peñéñory Article first published online: 19 DEC 2012 | DOI: 10.1002/ejoc.201201163 They have developed a one-pot methodology for the… Continue reading One-Pot Synthesis of Alkyl Styryl Sulfides Free from Transition Metal/Ligand Catalyst and Thiols
Month: December 2012
Total Synthesis and Structure Confirmation of Cryptocaryol A
Total Synthesis and Structure Confirmation of Cryptocaryol A European journal of chemistryEarly View (Online Version of Record published before inclusion in an issue) D. Srinivas Reddy and Debendra K. Mohapatra Article first published online: 19 DEC 2012 | DOI: 10.1002/ejoc.201201309 Maruoka asymmetric allylation, chelation-controlled 1,3-induced allylation, iterative iodocyclization and ring-closing metathesis reactions were used sequentially… Continue reading Total Synthesis and Structure Confirmation of Cryptocaryol A
Pinnick oxidation
The Pinnick oxidation is also known as Lindgren oxidation. It is an organic reaction by which aldehydes can be oxidized into its corresponding carboxylic acid, originally developed by Lindgren and Nilsson.ref1 The typical reaction condition used today was modified by G. A. Kraus even before Pinnick.ref2,3 Pinnick proved this condition as general. There are number of ways to oxidize the aldehydes however, only… Continue reading Pinnick oxidation
US 6894199, Process for the production of xylitol
(2R,4S)-Pentane-1,2,3,4,5-pentol Xylitol used to denote sugar alcohols) is a sugar alcohol sweetener used as a sugar substitute. Xylitol has the formula (CHOH)3(CH2OH)2 and is an achiral isomer of pentane-1,2,3,4,5-pentol. Xylitol is roughly as sweet as sucrose with 33% fewer calories. Unlike other sweeteners, xylitol is actively beneficial for dental health, reducing caries to a third in regular use, and has been shown to reduce… Continue reading US 6894199, Process for the production of xylitol
AVANAFIL, NEW DRUG FOR ERECTILE DYSFUNCTION, FDA APRIL 2012
Avanafil is a PDE5 inhibitor approved for erectile dysfunction on April 27, 2012.[1] Avanafil is known by the trademark name Stendra and was developed by Vivus Inc. It acts by inhibiting a specific phosphodiesterase type 5 enzyme which is found in various body tissues, but primarily in the corpus cavernosum penis, as well as the retina. Other similar drugs are sildenafil, tadalafil and vardenafil. The advantage of avanafil is that… Continue reading AVANAFIL, NEW DRUG FOR ERECTILE DYSFUNCTION, FDA APRIL 2012
New Data for Jakafi® (Ruxolitinib) to Be Presented at the 2012 American Society of Hematology Annual Meeting
Ruxolitinib (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile, CAS number 941678-49-5 Incyte Corporation (Nasdaq: INCY) announced today that several analyses from clinical studies of Jakafi® (ruxolitinib) will be presented at the 2012 American Society of Hematology (ASH) Annual Meeting from Dec. 8 to 11 , 2012 at the Georgia World Congress Center in Atlanta. Jakafi, an oral Janus kinase (JAK) inhibitor,… Continue reading New Data for Jakafi® (Ruxolitinib) to Be Presented at the 2012 American Society of Hematology Annual Meeting
FDA accepts AVEO-Astellas tivozanib NDA filing for renal cell carcinoma, 29 nov 2012
1-{2-Chloro-4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-3-(5-methylisoxazol-3-yl)urea AV-951 Tivozanib (AV-951) is an oral VEGF receptor tyrosine kinase inhibitor. It is undergoing clinical trial investigation for the treatment of renal cell carcinomas.[1] An oral quinoline urea derivative, tivozanib suppresses angiogenesis by being selectively inhibitory against vascular endothelial growth factor.[2] It was developed by AVEO Pharmaceuticals.[3] It is designed to inhibit all three VEGF receptors.[4] Phase III results on advanced renal cell carcinoma suggest a 30%… Continue reading FDA accepts AVEO-Astellas tivozanib NDA filing for renal cell carcinoma, 29 nov 2012